RxDoctor Payments Data

Nancy Ashmore

Family · Paris, TXNPI 1932561503

Payments from drug & device makers

$3,176in general payments, 2019–2025

Across 119 payments — averaging $26.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AbbVie$356
  • AstraZeneca$297
  • Novo Nordisk$270
  • Lilly USA, LLC$233
  • Idorsia Pharmaceuticals US Inc$217
  • plus $698 from 13 others

What the payments were for

  • Food & beverage$3,07797%
  • Education$993%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,176 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$100,863
Medicare patients
353
Services billed
1,850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$131,352
RybelsusSemaglutide24$36,795
JanuviaSitagliptin Phosphate18$28,464
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$27,054
VraylarCariprazine Hcl11$18,433
FarxigaDapagliflozin Propanediol13$11,388
XareltoRivaroxaban13$8,206
Levothyroxine Sodium325$2,779
Atorvastatin Calcium172$1,599
Testosterone Cypionate15$1,492
Metoprolol Succinate87$1,384
Metformin Hcl166$1,264
Gabapentin72$1,185
Albuterol Sulfate HfaAlbuterol Sulfate32$1,167
Potassium Chloride57$1,160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$270$168,147118 claims
GSKTrelegy Ellipta$1,104$27,05438 claims
AbbVieVraylar, Armour Thyroid$356$19,12325 claims
AstraZenecaFarxiga$297$11,38813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.

Other family in Paris

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →